Noven Pharmaceuticals

Noven Pharmaceuticals is a fully-integrated specialty pharmaceutical company with industry-leading transdermal expertise. Founded in 1987, the company is committed to developing and offering pharmaceutical products that meaningfully benefit patients, with a focus on advancing patient care through transdermal drug delivery. With over 300 colleagues working across locations in Miami, FL, and Jersey City, NJ, Noven Pharmaceuticals is dedicated to research, development, manufacture, marketing, and sale of prescription pharmaceutical products.

As a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., the world’s largest manufacturer of transdermal patches, Noven Pharmaceuticals serves as Hisamitsu's growth platform for U.S. prescription pharmaceuticals. The company maintains state-of-the-art, FDA-approved transdermal manufacturing facilities in Miami, with the capacity to produce several hundred million patches per year. These facilities are also approved by the U.S. DEA (Drug Enforcement Agency) for the production of controlled substances.

Noven Pharmaceuticals operates within the Biotechnology and Health Care industries, positioning itself as a dynamic player in the pharmaceutical sector, focused on innovation and patient-centric solutions. While specific details about the last investment and investors are not provided, Noven Pharmaceuticals' strong expertise, manufacturing capabilities, and strategic positioning within a growing market make it an intriguing prospect for venture capital investment.